Selective Hepatic Protein-Degradation Therapies for Treatment of Abnormal Liver Protein Accumulation

Abstract

Abnormal hepatic protein accumulation underlies a spectrum of liver pathologies, including genetic and acquired proteinopathies such as alpha-1 antitrypsin deficiency, hereditary transthyretin amyloidosis, and certain storage diseases. Targeted degradation of aberrant proteins represents a paradigm shift in hepatology, moving beyond traditional symptom management to directly address pathogenic protein load. This review synthesizes current knowledge on selective hepatic protein-degradation therapies, with a focus on molecular mechanisms, clinical efficacy, safety, and future directions, providing clinicians with an evidence-based perspective on this rapidly evolving therapeutic landscape.

Introduction

Chronic liver diseases characterized by abnormal intrahepatic protein accumulation pose significant diagnostic and therapeutic challenges. The resultant hepatocellular dysfunction and progressive liver injury are implicated in substantial morbidity and mortality worldwide. In recent years, advances in molecular biology and pharmacology have catalyzed the development of selective hepatic protein-degradation therapies, enabling targeted removal of pathogenic proteins. This article reviews the epidemiology, pathophysiology, risk factors, clinical features, diagnostic approaches, treatment modalities, emerging therapies, and guideline-based recommendations regarding these novel interventions, with an emphasis on clinical applicability and translational potential.

Epidemiology / Disease Burden

Protein misfolding and aggregation disorders such as alpha-1 antitrypsin (AAT) deficiency, hereditary amyloidoses, and certain metabolic storage diseases contribute to a significant global burden of chronic liver disease. AAT deficiency alone affects approximately 1 in 2,500 individuals of European descent, often leading to cirrhosis and hepatocellular carcinoma. The prevalence of hepatic amyloidosis and related disorders, although rarer, is increasing due to improved diagnostic modalities and aging populations. Collectively, protein-accumulation hepatopathies are under-recognized contributors to liver-related morbidity, emphasizing the need for disease-modifying interventions.

Pathophysiology

Pathogenic protein accumulation in hepatocytes typically results from genetic mutations affecting protein folding, trafficking, or degradation. For instance, the Z allele in AAT deficiency causes misfolded AAT protein retention within the endoplasmic reticulum (ER), triggering ER stress, hepatocyte injury, and inflammation. In hereditary transthyretin amyloidosis, mutant transthyretin forms insoluble aggregates that deposit within hepatic and extrahepatic tissues. Ineffective clearance of these proteins overwhelms proteostatic mechanisms, initiating cellular dysfunction, apoptotic pathways, and progressive fibrosis. Understanding these mechanistic underpinnings has illuminated the therapeutic potential of enhancing selective protein degradation in the liver.

Risk Factors

Risk factors for hepatic protein-accumulation disorders are primarily genetic, with autosomal codominant or dominant inheritance patterns. Environmental and metabolic factors, such as alcohol use, viral hepatitis, obesity, and metabolic syndrome, can exacerbate disease progression by increasing hepatocellular stress and impairing protein clearance. Moreover, polymorphisms in genes encoding proteostasis regulators or autophagy-related proteins may modulate individual susceptibility and response to therapies targeting protein degradation.

Clinical Features

Clinical manifestations are heterogeneous, ranging from asymptomatic elevations in liver enzymes to fulminant hepatic failure. In AAT deficiency, patients may present with neonatal cholestasis, chronic hepatitis, or cirrhosis, while amyloidosis manifests with hepatomegaly, cholestasis, and, occasionally, portal hypertension. Non-specific symptoms such as fatigue, jaundice, and abdominal discomfort are common, underscoring the importance of high clinical suspicion in at-risk populations.

Diagnosis

Diagnosis is multifaceted and relies on a combination of clinical assessment, biochemical testing, genetic analysis, and histopathology. Serum protein quantification (e.g., AAT levels), protein phenotype analysis, and specific mutation detection are essential for definitive diagnosis. Liver biopsy with immunohistochemical staining can demonstrate intrahepatic protein aggregates, while advanced imaging modalities and mass spectrometry enhance diagnostic accuracy. Recent advances in liquid biopsy and proteomics may soon offer minimally invasive alternatives for disease monitoring.

Treatment & Management

Conventional management of protein-accumulation hepatopathies has centered on supportive care, avoidance of exacerbating factors, and management of complications such as portal hypertension and liver failure. Liver transplantation remains the definitive therapeutic option for end-stage disease; however, the advent of molecularly targeted therapies has expanded the therapeutic arsenal. Pharmacological chaperones, proteostasis regulators, and gene-silencing agents have shown promise in modulating hepatic protein load.

Recent Advances / Emerging Therapies

Selective protein-degradation strategies harness endogenous cellular pathways, such as the ubiquitin-proteasome system (UPS) and autophagy-lysosome pathway, to enhance removal of deleterious proteins. Proteolysis targeting chimeras (PROTACs), small molecules that induce targeted ubiquitination and degradation of disease-causing proteins, have demonstrated preclinical efficacy in hepatic models. Similarly, RNA interference (RNAi) therapeutics, including small interfering RNAs (siRNAs) and antisense oligonucleotides (ASOs), have entered clinical trials for AAT deficiency and transthyretin amyloidosis, leading to significant reductions in pathogenic protein synthesis and hepatic deposition. Early-phase studies of autophagy inducers and ER stress modulators have further highlighted the therapeutic potential of modulating intracellular degradation pathways.

Guideline Recommendations

Recent consensus statements and guidelines from hepatology and rare disease societies now endorse the use of targeted therapies, where available, for eligible patients with confirmed protein-accumulation disorders. For example, the American Association for the Study of Liver Diseases (AASLD) recommends consideration of RNAi therapies for hereditary transthyretin amyloidosis and investigational therapies for AAT deficiency in clinical trial settings. Transplantation remains reserved for patients with advanced, refractory disease. Ongoing monitoring of hepatic function and protein levels is essential to guide therapy and assess response.

Conclusion

The advent of selective hepatic protein-degradation therapies marks a transformative era in the management of protein-accumulation liver diseases. By targeting the root cause of hepatocellular injury, these innovative approaches offer the potential to halt or reverse disease progression, reduce the need for transplantation, and improve patient outcomes. While long-term safety and real-world efficacy data are evolving, integration of these therapies into clinical practice requires a multidisciplinary approach, careful patient selection, and rigorous post-marketing surveillance. Continued research into the molecular basis of hepatic proteostasis and development of next-generation degraders will further refine and expand therapeutic options for affected patients.